Pilot randomized, placebo-controlled, double-blind study in subjects aged 3–18 years with T1DM, GAD-65 and/or islet cell antibody positivity, HbA1c >6% at diagnosis. The gene discussed is GAD2; the disease is type 1 diabetes mellitus.